Free Newsletter
Texas sues J&J's Janssen Pharma
The state of Texas is suing Johnson & Johnson's Janssen Pharmaceuticals, alleging that the drug company used Texas mental health officials as "pitchmen" and carried out other unseemly tactics to get its antipsychotic medication, Risperdal, on Texas's Medicaid preferred provider drug list. In addition, the state is accusing New Jersey-based Janssen of supplying phony advocacy groups and making other attempts to influence positioning of the medication, essentially defrauding the state over the last 10 years. Report
More stories about Risperdal Medicaid Fraud Texas Drug Marketing Janssen Pharmaceuticals Johnson & Johnson
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





